EUVIMEDEUVIMED entdecken
Crossref

Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study

Mehmet Erdem Cakmak, Nida Öztop, Osman Ozan Yeğit

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000534907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Mehmet Erdem Cakmak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Eosinophilia, Sinusitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Severe asthma is characterized by frequent recurrent airway symptoms and exacerbations, and these affect the quality of life. Biological agents can be used in the treatment of patients with severe asthma if the disease cannot be controlled with standard controller treatment. The aim of this study was to compare the clinical characteristics and laboratory data of patients with severe asthma who were switched from omalizumab to mepolizumab and patients with severe asthma who responded to omalizumab.

Methods

The clinical characteristics and laboratory data of patients with severe asthma who responded to omalizumab and switched from omalizumab to mepolizumab were compared retrospectively.

Results

Evaluation was made of a total of 79 patients, including 64 omalizumab responders and 15 who switched to mepolizumab from omalizumab. After omalizumab and mepolizumab treatment, the annual number of asthma attacks, the use of oral corticosteroid (OCS), the annual number of hospitalizations, and the eosinophil count significantly decreased (omalizumab: p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively; mepolizumab: p = 0.001, p = 0.001, p = 0.002, p = 0.001, respectively). After omalizumab treatment, the increase in forced expiratory volume in 1 s (FEV1) (%) and asthma control test (ACT) score were determined to be statistically significant (p < 0.001, p < 0.001, respectively). After mepolizumab treatment, the increase in ACT score was significant (p = 0.003). Drug allergy, chronic sinusitis with nasal polyps (CRSwNP), regular use of OCS, and high baseline eosinophil count (cells/µL) were associated with poor response to omalizumab treatment (odds ratio [OR] = 7.86, p = 0.003; OR = 52.92, p < 0.001; OR = 10.16, p = 0.004; OR = 0.99, p = 0.004, respectively). House dust mite sensitivity and high baseline FEV1 (%) were associated with good response to omalizumab treatment (OR = 0.29, p = 0.041; OR = 1.06, p = 0.03, respectively). The blood eosinophil count had diagnostic value in predicting the nonresponsiveness to omalizumab treatment (area under the curve [AUC]: 0.967, p < 0.001, cut-off: 510).

Conclusion

A high pretreatment eosinophil count, concomitant CRSwNP, a history of drug allergy, and regular OCS use may be associated with poor response to omalizumab treatment in patients with severe asthma. Depending on the treatment response, treatment switching can be applied between biological agents. The results of the current study should be supported by multicenter studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaEosinophiliaSinusitisDrug HypersensitivityAntibodies, Monoclonal, HumanizedHumansOmalizumabQuality of LifeRetrospective StudiesChronic DiseaseAdrenal Cortex Hormones

Stichwörter der Autor:innen

Anti-immunoglobulin EAsthmaBiologicsMepolizumabOmalizumab

Substanzen

OmalizumabmepolizumabAnti-Asthmatic AgentsAdrenal Cortex HormonesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.

Zitieren

APA

Cakmak, M. E., Öztop, N., & Yeğit, O. O. (2024). Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000534907

Vancouver

Cakmak ME, Öztop N, Yeğit OO. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study. International Archives of Allergy and Immunology. 2024. doi:10.1159/000534907

BibTeX
@article{Cakmak2024,
  author = {Cakmak, Mehmet Erdem and Öztop, Nida and Yeğit, Osman Ozan},
  title = {Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000534907}
}
Kostenlos starten →